Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | P2RY6 | Q15077 | 11/20 | 0.50 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.50 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL543054 | 1.00 | POLG (0.60) | POLGPOLBP2RY6P2RY2P2RY4 | |
| SCHEMBL543438 | 0.93 | POLG (0.67) | POLGPOLBP2RY6P2RY2P2RY4 | |
| SCHEMBL543711 | 0.93 | POLG (0.49) | POLGPOLBP2RY6P2RY2P2RY4 | |
| Ddctp SCHEMBL210922 | 0.92 | POLG (0.70) | POLGPOLBP2RY6P2RY2P2RY4 | |
| Ddctp SCHEMBL16807754 | 0.92 | POLG (0.70) | POLGPOLBP2RY6P2RY2P2RY4 | |
| Ddctp SCHEMBL30586989 | 0.92 | POLG (0.70) | POLGPOLBP2RY6P2RY2P2RY4 | |
| Ddctp SCHEMBL20879464 | 0.92 | POLG (0.70) | POLGPOLBP2RY6P2RY2P2RY4 | |
| Ddctp SCHEMBL18840498 | 0.92 | POLG (0.70) | POLGPOLBP2RY6P2RY2P2RY4 | |
| SCHEMBL19389365 | 0.86 | POLG (0.54) | POLGPOLBP2RY6P2RY2P2RY4 | |
| SCHEMBL23157013 | 0.85 | POLG (0.55) | POLGPOLBP2RY6P2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110676-B2 | Prodrugs activated by RNA-dependent DNA-polymerases | PROTERA S.R.L. (IT) | 2012-02-07 | — | — | US | disclosed |
| US-20080300215-A1 | Prodrugs Activated by Rna-Dependent Dna-Polymerases | PROTERA S.R.L. (IT) | 2008-12-04 | — | — | US | disclosed |
| EP-1778254-A2 | PRODRUGS ACTIVATED BY RNA-DEPENDENT DNA-POLYMERASES | Protera S.R.L. (IT) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006013203-A2 | PRODRUGS ACTIVATED BY RNA-DEPENDENT DNA-POLYMERASES | PROTERA S.R.L. (IT) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300215-A1 | Prodrugs Activated by Rna-Dependent Dna-Polymerases | TERT, POLRMT, POLI | POLG 42/4885POLB 8/4885P2RY6 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.